Glucose-insulin interactions during cardiopulmonary bypass. Hypothermia versus normothermia.
Since hypothermia is commonly used to lower local and general metabolism during cardiopulmonary bypass, we attempted to identify its specific effects on glucose-insulin interactions. A group of nondiabetic patients undergoing hypothermic (28 degrees C) cardiopulmonary bypass with ischemic (cold) cardiac arrest was compared to a similar group operated on under normothermic conditions with potassium cardioplegia. In the absence of exogenous dextrose administration, hypothermia blocked insulin secretion for the duration of the operation. It also inhibited insulin secretion in response to an exogenous dextrose load (e.g., the priming fluid of the cardiopulmonary bypass circuit) or a glucagon injection, but this inhibition was lifted by rewarming. Blood glucose levels, which during normothermia were mildly elevated even in the absence of dextrose administration, remained normal during the hypothermic phase of cardiopulmonary bypass. By the end of the rewarming period, however, blood glucose levels had reached the same level as observed under normothermic bypass, a fact suggesting that the cold inhibition of hepatic glucose production had been only temporary. Cold inhibition of hepatic glucose production also explains why glucose clearance after a sudden dextrose load was initially faster at low body temperature than at normal temperature. Glucose-clamp studies indicated that insulin resistance was initiated by anesthesia and surgical trauma, and further accentuated by cardiopulmonary bypass, in association with elevated levels of hormones indicative of surgical stress. Regardless of body temperature changes, the assimilation of glucose by nondiabetic subjects during and immediately after bypass called for the infusion of large doses of insulin. A comparison with diabetic subjects showed that insulin-dependent patients (type I diabetes) required no more insulin during cardiopulmonary bypass than normal subjects, whereas patients with type II diabetes exhibited a marked insulin resistance during the operation and in the immediate postoperative period.
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D002315:Cardiopulmonary Bypass; D004837:Epinephrine / Q000097:blood; D005260:Female; D005934:Glucagon; D005947:Glucose / Q000378:metabolism* / Q000494:pharmacology; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007036:Hypothermia, Induced / Q000379:methods; D007328:Insulin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009638:Norepinephrine / Q000097:blood
D001786:Blood Glucose; D007328:Insulin; D013006:Growth Hormone; D005934:Glucagon; D005947:Glucose; D009638:Norepinephrine; D004837:Epinephrine